HK1205740A1 - Pyrrolotriazinone derivatives - Google Patents

Pyrrolotriazinone derivatives

Info

Publication number
HK1205740A1
HK1205740A1 HK15106267.6A HK15106267A HK1205740A1 HK 1205740 A1 HK1205740 A1 HK 1205740A1 HK 15106267 A HK15106267 A HK 15106267A HK 1205740 A1 HK1205740 A1 HK 1205740A1
Authority
HK
Hong Kong
Prior art keywords
pyrrolotriazinone derivatives
pyrrolotriazinone
derivatives
Prior art date
Application number
HK15106267.6A
Other languages
English (en)
Chinese (zh)
Inventor
Dieter Dorsch
Hans-Peter Buchstaller
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HK1205740A1 publication Critical patent/HK1205740A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
HK15106267.6A 2012-05-04 2015-07-02 Pyrrolotriazinone derivatives HK1205740A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12003445 2012-05-04
PCT/EP2013/001026 WO2013164061A1 (en) 2012-05-04 2013-04-06 Pyrrolotriazinone derivatives

Publications (1)

Publication Number Publication Date
HK1205740A1 true HK1205740A1 (en) 2015-12-24

Family

ID=48050660

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106267.6A HK1205740A1 (en) 2012-05-04 2015-07-02 Pyrrolotriazinone derivatives

Country Status (22)

Country Link
US (1) US9174995B2 (es)
EP (1) EP2844659B1 (es)
JP (1) JP6097820B2 (es)
KR (1) KR20150006873A (es)
CN (1) CN104271580B (es)
AR (1) AR090896A1 (es)
AU (1) AU2013257018B2 (es)
CA (1) CA2872334C (es)
EA (1) EA027628B1 (es)
ES (1) ES2587939T3 (es)
HK (1) HK1205740A1 (es)
HR (1) HRP20161033T1 (es)
HU (1) HUE028325T2 (es)
IL (1) IL235414A (es)
MX (1) MX357502B (es)
PL (1) PL2844659T3 (es)
PT (1) PT2844659T (es)
RS (1) RS55062B1 (es)
SG (1) SG11201406997WA (es)
SI (1) SI2844659T1 (es)
WO (1) WO2013164061A1 (es)
ZA (1) ZA201408876B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013229229B2 (en) 2012-03-07 2017-10-19 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
NO3044221T3 (es) 2013-09-11 2018-07-21
LT3087076T (lt) * 2013-12-23 2017-12-27 Merck Patent Gmbh Imidazopirazinono dariniai
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
DK3130592T3 (da) 2014-04-10 2019-11-04 Hubei Bio Pharmaceutical Industrial Tech Institute Inc ANALOGER AF 4H-PYRAZOLO[1,5-á]BENZIMIDAZOL-FORBINDELSER SOM PARPINHIBITORER
KR20160007347A (ko) * 2014-07-11 2016-01-20 에스티팜 주식회사 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도
KR101775356B1 (ko) * 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
DK3356345T3 (da) 2015-09-30 2024-02-12 Max Planck Gesellschaft Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
PL3377495T3 (pl) 2015-11-16 2022-05-16 Topadur Pharma Ag Pochodne 2-fenylo-3,4-dihydropirolo[2,1-f] [1,2,4]triazynonu jako inhibitory fosfodiesterazy i ich zastosowania
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
CN109180702B (zh) * 2018-10-29 2021-11-30 四川大学 一种噻吩并嘧啶酮化合物及其用途
CN111961058B (zh) * 2020-08-03 2022-12-16 天津全和诚科技有限责任公司 4-氨基-吡咯并三嗪衍生物及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
KR20030013433A (ko) 2000-05-31 2003-02-14 아스트라제네카 아베 혈관 손상 활성을 가진 인돌 유도체
EP1301497A1 (en) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
US7223766B2 (en) * 2003-03-28 2007-05-29 Scios, Inc. Bi-cyclic pyrimidine inhibitors of TGFβ
BRPI0516751A (pt) * 2004-09-30 2008-09-16 Tibotec Pharm Ltd pirimidinas bicìclicas que inibem hcv
WO2008092861A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
ES2381446T3 (es) * 2007-03-08 2012-05-28 Janssen Pharmaceutica, N.V. Derivado de quinolinona como inhibidores de PARP y TANK
WO2008131050A1 (en) * 2007-04-18 2008-10-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
WO2013164061A1 (en) 2013-11-07
EA027628B1 (ru) 2017-08-31
CN104271580A (zh) 2015-01-07
KR20150006873A (ko) 2015-01-19
RS55062B1 (sr) 2016-12-30
AU2013257018A1 (en) 2014-12-18
EA201401212A1 (ru) 2015-08-31
EP2844659A1 (en) 2015-03-11
US9174995B2 (en) 2015-11-03
JP6097820B2 (ja) 2017-03-15
PL2844659T3 (pl) 2016-11-30
US20150133453A1 (en) 2015-05-14
AR090896A1 (es) 2014-12-17
WO2013164061A8 (en) 2014-11-06
SI2844659T1 (sl) 2016-10-28
JP2015515961A (ja) 2015-06-04
AU2013257018B2 (en) 2017-02-16
CA2872334A1 (en) 2013-11-07
ES2587939T3 (es) 2016-10-27
HUE028325T2 (en) 2016-12-28
MX357502B (es) 2018-07-12
PT2844659T (pt) 2016-08-31
ZA201408876B (en) 2017-06-28
CN104271580B (zh) 2017-02-22
MX2014013090A (es) 2014-12-08
EP2844659B1 (en) 2016-05-25
CA2872334C (en) 2020-06-30
SG11201406997WA (en) 2014-11-27
HRP20161033T1 (hr) 2016-10-21
IL235414A (en) 2017-11-30

Similar Documents

Publication Publication Date Title
HUS2200040I1 (hu) Benzimidazol-prolin származékok
HK1205740A1 (en) Pyrrolotriazinone derivatives
DK2830816T3 (en) Hidtil ukendt coatingkoncept
HK1207375A1 (en) Piperidinylpyrazolopyridine derivative
HK1205508A1 (en) New bicyclicpyridine derivatives
IL236295A (en) The history of indanesulfamide
ZA201502175B (en) Oxazolidin-2-one-pyrimidine derivatives
PL2838883T3 (pl) Nowe pochodne fenylo-tetrahydroizochinoliny
HK1200824A1 (en) Substituted phenylazole derivative
EP2873660A4 (en) INDOLCARBOXAMIDDERIVAT
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
EP2842958A4 (en) NAPHTHOBISTHIADIAZOLDERIVAT
HK1204621A1 (en) 4-alkanoylamino-3-pyrazolone derivative 4--3-
AU345893S (en) Treehouse

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210402